Spyre Therapeutics (SYRE) Income towards Parent Company (2015 - 2026)
Spyre Therapeutics (SYRE) posted Income towards Parent Company of -$69.0 million for Q1 2026, down 10.36% on a QoQ basis from -$62.5 million in Q4 2025, and down 54.12% year-over-year from -$150.4 million in Q1 2025.
Spyre Therapeutics (SYRE) Income towards Parent Company (2015 - 2026) Analysis & Trends
Spyre Therapeutics' Income towards Parent Company history runs 12 years deep, the most recent figure standing at -$69.0 million for Q1 2026.
- Quarterly Income towards Parent Company fell 54.12% year-over-year to -$69.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$179.4 million (up 14.12% YoY) and the FY2025 annual result came in at -$155.2 million, up 25.39% from the prior year.
- Income towards Parent Company was -$69.0 million for Q1 2026 at Spyre Therapeutics, down from -$62.5 million in the prior quarter.
- Across five years, Income towards Parent Company topped out at -$11.2 million in Q3 2025 and bottomed at -$217.1 million in Q2 2023.
- A 5-year average of -$50.3 million and a median of -$40.1 million in 2023 frame the typical range for Income towards Parent Company.
- Annual changes were most pronounced in 2023 — Income towards Parent Company plunged 872.45% — and 2025, when it surged 83.8%.
- Spyre Therapeutics' Income towards Parent Company stood at -$18.8 million in 2022, then plunged by 235.67% to -$63.2 million in 2023, then grew by 10.9% to -$56.3 million in 2024, then dropped by 11.07% to -$62.5 million in 2025, then fell by 10.36% to -$69.0 million in 2026.
- Business Quant data shows SYRE's Income towards Parent Company at -$69.0 million in Q1 2026, -$62.5 million in Q4 2025, and -$11.2 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - |
| 10 | Spyre Therapeutics | 259.59 Mn | 259.59 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -69.01 Mn |
| Dec 31, 2025 | -62.53 Mn |
| Sep 30, 2025 | -11.18 Mn |
| Jun 30, 2025 | -36.72 Mn |
| Mar 31, 2025 | -44.77 Mn |
| Dec 31, 2024 | -56.30 Mn |
| Sep 30, 2024 | -69.03 Mn |
| Jun 30, 2024 | -38.84 Mn |
| Mar 31, 2024 | -43.86 Mn |
| Dec 31, 2023 | -63.18 Mn |
| Sep 30, 2023 | -40.11 Mn |
| Jun 30, 2023 | -217.08 Mn |
| Mar 31, 2023 | -18.42 Mn |
| Dec 31, 2022 | -18.82 Mn |
| Sep 30, 2022 | -18.23 Mn |
| Jun 30, 2022 | -22.32 Mn |
| Mar 31, 2022 | -24.44 Mn |
| Dec 31, 2021 | -20.45 Mn |
| Sep 30, 2021 | -20.31 Mn |
| Jun 30, 2021 | -6.83 Mn |